Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell™) at ASGCT 2022
20. Mai 2022 06:00 ET
|
Smart Immune
PARIS, May 20, 2022 (GLOBE NEWSWIRE) -- Smart Immune, a clinical-stage biotechnology company focused on saving and improving lives by delivering to patients a new generation of thymus-empowered T...
Smart Immune Announces Research Collaboration with Memorial Sloan Kettering Cancer Center (MSK) to Expedite Development of a Next Generation CAR-T Through its Long Lasting, Exhaustion-Free CAR ProTcell™ Platform
09. Dezember 2021 05:30 ET
|
Smart Immune
PARIS, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a clinical stage T-cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus-in-a-dish” technology to develop T-cell...
Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology
05. November 2021 05:30 ET
|
Smart Immune
PARIS, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a T-cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell...
Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcell™) for AML and ALL
13. Oktober 2021 07:00 ET
|
Smart Immune
PARIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell...
TNFα-supplemented DL-4 culture system supports first-in-clinic Smart Immune ProTcell™ technology for immuno-deficient patients fighting cancers and infections
29. September 2021 09:00 ET
|
Smart Immune
PARIS, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS’s unique ex-vivo biomimetic ProTcell™ ‘thymus in a dish’ platform technology, designed to generate specific human T-cell progenitor cells...
Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell Progenitor Product SMART 101 (ProTcell™) for AML and ALL
10. Mai 2021 05:30 ET
|
Smart Immune
PARIS, May 10, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop proprietary allogeneic T...